Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B
Gut and Liver
;
: 611-616, 2016.
Article
in English
| WPRIM
| ID: wpr-164311
ABSTRACT
BACKGROUND/AIMS:
Despite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion. We aimed to explore the potential efficacy of combination therapy consisting of pegylated interferon (p-IFN) and an oral antiviral agent in patients with HBeAg-positive chronic hepatitis B.METHODS:
The treatment protocol consisted of p-IFN-α-2a at 180 μg/wk for 48 weeks, with either entecavir or tenofovir added 8 weeks after the initiation of p-IFN and continued for at least 6 months after HBe seroconversion was achieved.RESULTS:
To date, 10 patients have been treated under the protocol (eight adults, mean age 36±8 years; two adolescents, aged 12 and 16 years). All eight adult patients experienced loss of HBeAg at a mean of 72.3±66.9 weeks, including six patients who also developed anti-HBe and one patient who had HBs seroconversion. Although both adolescents remain on therapy, one adolescent had HBs seroconversion without HBe seroconversion. A total of nine of our 10 patients experienced a favorable serological transition.CONCLUSIONS:
The combination of p-IFN and a modern oral antiviral agent may be more effective than monotherapy with either class of agent in the treatment of HBeAg-positive chronic hepatitis B patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Clinical Protocols
/
Hepatitis B virus
/
Interferons
/
Hepatitis B, Chronic
/
Tenofovir
/
Seroconversion
/
Hepatitis B
/
Hepatitis B e Antigens
/
Hepatitis, Chronic
Type of study:
Practice guideline
Limits:
Adolescent
/
Adult
/
Humans
Language:
English
Journal:
Gut and Liver
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS